Roche’s Tecentriq gains new US lung cancer indication

Roche’s Tecentriq gains new US lung cancer indication

Source: 
Pharmaforum
snippet: 

Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination with chemotherapy.